InnaVirVax nabs $4.9M in B round to advance HIV immunotherapy

French biotech InnaVirVax has rallied investors to pump $4.9 million into its coffers via a Series B round of financing. The company will use the proceeds to begin trials of its drug VAC-3S, which is intended to boost the immune systems of HIV-infected patients. Investors in the round included lead backers Fa Dièse and Fonds Régional de Co-Investissement d'Ile-de-France, along with contributions from CapDecisif 2 and G1J Ile-de-France. "Thanks to them, we will be able to carry out the first in man study with our VAC-3S immunotherapy, for which we received the authorization from the AFSSAPS (the French Drug Agency)," InnaVirVax CEO Joël Crouzet explained in a statement. "Based on a cutting edge discovery aiming at protecting the immune system in HIV-infected patients, this candidate immunotherapy represents a fantastic challenge and we think that it should be an effective therapeutic answer for patients at different stages of the disease." Release